Tenax Therapeutics Inc. stocks have been trading up by 11.08 percent amid heightened optimism from its latest clinical progress news
Click Here for a Millionaire's POV on Trading TENX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Canaccord Genuity initiated coverage on Tenax Therapeutics with a Buy rating and a $35 price target, highlighting TNX-103 for pulmonary hypertension in HFpEF, an underserved market with no approved therapies.
- A key clinical milestone, the first LEVEL trial readout for PH-HFpEF, is expected at next month’s European Society of Cardiology Congress, with Canaccord modeling a 60% probability of success but still seeing significant upside potential.
- Tenax Therapeutics reported Q2 EPS of -$0.35, slightly better than consensus of -$0.36, and highlighted upcoming topline data in August from its LEVEL trial for PH-HFpEF.
- Tenax is continuing enrollment and site activation for LEVEL-2, a second global pivotal trial of TNX-103, with targeted enrollment completion by the end of 2027.
- Leerink sharply cut its price target on Tenax Therapeutics from $26 to $4 but maintained an Outperform rating, signaling reduced upside expectations while still viewing the stock as attractive relative to current levels.
Live Update At 09:17:22 EDT: On Tuesday, August 25, 2026 Tenax Therapeutics Inc. stock [NASDAQ: TENX] is trending up by 11.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TENX is trading like a classic biotech event play. After a sharp post-earnings and news reset from the mid-teens down to the high $1s, Tenax Therapeutics has stabilized, with recent closes clustering between $1.70 and $1.90. That’s a huge slide from the late July range near $13–$15, but the sideways action in August tells traders the market is now waiting on one thing: data.
On the intraday tape, TENX has been pinned around $2 with tight five‑minute candles between roughly $1.98 and $2.08. That lack of range signals consolidation rather than panic. Short-term, it’s more of a coiled spring than a breakdown.
More Breaking News
- BDRX Stock Attracts Traders As Phase 3 Trial Crosses Key Milestone
- PSNYW Warrant Trading Volatile As Polestar’s Numbers Tighten
- OFAL Stock Whipsaws As Traders Zero In On Dilution, Deep Losses
- Intel Stock Draws Nvidia Backing As $20B Equity Raise Powers AI Push
Fundamentally, Tenax Therapeutics remains a development-stage name. Q2 EPS came in at -$0.35, almost exactly in line with expectations of -$0.36. Operating cash burn of about $14.2M in the quarter is meaningful, but the balance sheet shows $117.976M in cash and restricted cash, a very strong current ratio of 15.1, and no debt. TENX is losing money (negative returns on equity and assets), but that’s normal for a small-cap biotech heading into pivotal trial readouts. For active trading, the key is not the backward EPS miss or beat — it’s how long the cash runway supports TNX‑103 and the LEVEL program into 2027.
Why Traders Are Watching TENX Right Now
TENX is squarely in the spotlight because Wall Street has made its bet: if TNX‑103 works in pulmonary hypertension with HFpEF, the upside case is big. Canaccord Genuity just initiated Tenax Therapeutics with a Buy rating and a $35 price target, explicitly calling out TNX‑103 and the upcoming LEVEL trial readout at the European Society of Cardiology Congress next month. They even assign a 60% probability of success, which is high for a binary biotech catalyst.
That initiation lines up with a broader Street view. Other coverage has Tenax Therapeutics around a $35.22 average target, also rated Buy on average. For traders, that means TENX is not a lonely contrarian call — there is a real consensus that, at current prices near $2, the risk‑reward skew is substantial if the PH‑HFpEF data are positive.
At the same time, the story is not all blue skies. Leerink just slashed its TENX price target from $26 down to $4, while still keeping an Outperform rating. That is a massive reset and a clear reminder that even bullish analysts are recalibrating how much value they assign before the data hit the tape. For short-term trading, this split backdrop creates opportunity and danger. Positive headlines into August and the Congress could squeeze shorts and draw momentum traders into TENX. Disappointing or even “just okay” data could push the stock closer to that $4 target — or below — given how far it has already fallen from July levels.
Meanwhile, Tenax Therapeutics is not standing still. Management is pushing ahead with LEVEL‑2, a second global pivotal trial of TNX‑103, targeting full enrollment by the end of 2027. That second trial matters because, in biotech land, one positive readout is good, but two confirmatory datasets are how drugs get across the regulatory finish line. For swing traders, that extended development arc means TENX is not just a one‑day binary bet; it’s a multi-year story with multiple catalysts and plenty of volatility in between.
Conclusion
For active traders, TENX is shaping up as a textbook catalyst stock. Tenax Therapeutics just printed an in‑line Q2 loss, but the cash pile near $118M and zero debt give the company room to run its TNX‑103 program through the upcoming LEVEL readout and deeper into LEVEL‑2. The chart shows a brutal reset from the teens to under $2, followed by tight consolidation — exactly the type of base that often precedes a big move when fresh news hits.
On the sentiment front, TENX sits at an interesting crossroads. Canaccord and other firms are pinning Buy ratings and ~$35 targets on Tenax Therapeutics, framing PH‑HFpEF as a large, completely unmet market. Leerink’s decision to chop its target from $26 to $4, while still calling the stock Outperform, injects a sharp dose of realism about risk and valuation. Together, those calls tell traders that the Street sees real potential but is also bracing for wide trading swings around the European Society of Cardiology data.
This is exactly the sort of setup Tim Sykes and his community study every day — liquid small caps with clear catalysts and emotional price action. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. As Sykes likes to remind traders, “The key is to react, not predict — trade the price action, cut losses quickly, and never fall in love with a story.” TENX fits that playbook perfectly. For educational and research-focused traders, Tenax Therapeutics is a name to keep on the screen as the LEVEL trial clock winds down.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.